17 results about "Synovial membrane" patented technology

This invention discloses a novel application of the RNA-binding protein HNRNPA1 in regulating copper death in synovial fibroblasts of rheumatoid arthritis (RA-FLS). Overexpression of HNRNPA1 recognizes and binds to the m6A modification site of SLC3A2 mRNA, enhancing its transcript stability, restoring the expression of SLC3A2 and copper death-related proteins, reducing MDA levels, increasing copper ion concentration and the activity of antioxidant enzymes SOD and POD, thereby repairing mitochondrial ultrastructural damage, inhibiting abnormal cell proliferation, and inducing apoptosis. Reversal experiments confirmed that knocking down SLC3A2 reverses the above effects, indicating that SLC3A2 is a core downstream target of HNRNPA1-mediated copper death. This invention reveals for the first time the decisive role of the HNRNPA1-SLC3A2-copper death axis in the pathological phenotype of RA-FLS, providing a new target for molecular intervention in rheumatoid arthritis.

The application discloses a multi-component synovitis treatment composition based on repairing cartilage tissue and application thereof, and relates to the technical field of biological medicine, and the composition is composed of glucosamine hydrochloride, chondroitin sulfate, dimethyl sulfone and graded molecular weight sodium hyaluronate; the application precisely compounding the graded molecular weight sodium hyaluronate with the glucosamine hydrochloride, the chondroitin sulfate and the dimethyl sulfone according to weight parts, constructs a gradient slow-release and target delivery system of synovitis lesions, specifically inhibits the activity of hyaluronidase in the inflammatory joint cavity by using the dimethyl sulfone, greatly reduces the degradation of the sodium hyaluronate, prolongs the residence time of the active ingredients at the lesion site, realizes immediate analgesia and relieves joint stiffness by quickly forming a lubricating protective film by the high molecular weight sodium hyaluronate, the medium and low molecular weight sodium hyaluronate penetrates the synovial membrane barrier and carries the cartilage repair components to enrich in the cartilage defect area, and the synergistic effect of the components is realized.

This invention discloses a chitosan-based lidocaine formulation for intra-articular use and its preparation method. Belonging to the field of pharmaceutical formulation technology, the formulation is prepared from chitosan, carboxymethyl chitosan, lidocaine, chitosan-PNIPAM microspheres, sulfated trehalose, and excipients. The chitosan-PNIPAM used in this invention exhibits dual temperature and pH response. With temperature changes, PNIPAM possesses both hydrophobic contractile and hydrophilic swelling states, thereby controlling the lidocaine release rate. Simultaneously, when the pH decreases, chitosan repels PNIPAM, further disintegrating the microspheres to release the drug, thus achieving targeted analgesia. Sulfated trehalose, as a cartilage matrix synthesis promoter, can activate intracellular signaling pathways in chondrocytes, promoting the synthesis of type II collagen and proteoglycans. Simultaneously, the sulfate groups can form electrostatic complexes with the amino groups of chitosan, enhancing drug retention. The formulation of this invention can inhibit synovial cells, release cytokines, and synergistically with carboxymethyl chitosan, increase the inhibition rate of inflammatory factors by 40%-50%.

The application belongs to the technical field of biological medicine, and discloses application of oridonin in preparation of a medicine for treating rheumatoid arthritis synovitis. For the first time, it is confirmed that oridonin takes glyceraldehyde-3-phosphate dehydrogenase as a direct action target, covalently combines through an α, β-unsaturated ketone, inhibits enzyme activity, blocks abnormal glycolysis of rheumatoid arthritis synovial cells, activates a KEAP1-NRF2 / HO-1 antioxidant anti-inflammatory pathway, inhibits an NF-κB inflammatory signal, and intervenes in a pathological process of rheumatoid arthritis synovitis from multiple dimensions, thereby providing a scientific basis for clinical application and deep development of oridonin against RA synovitis. A medicine composition containing oridonin and application of the medicine composition in preparation of an anti-rheumatoid arthritis synovitis medicine are disclosed. The application has advantages of target point precision, remarkable curative effect, high safety, mechanism innovation and the like, and provides a brand-new scheme for clinical treatment of rheumatoid arthritis synovitis.

This invention belongs to the field of traditional Chinese medicine preparations, and relates to the preparation method and application of a compound preparation of Yao Yu effervescent tablets with anti-rheumatoid arthritis effect. The compound preparation comprises the following traditional Chinese medicine components: 4 parts by weight of Dioscorea cirrhosa, 3 parts by weight of Tinleaf Vine, 2 parts by weight of Camphor Tree, 2 parts by weight of Rhus chinensis, 3 parts by weight of Rhododendron molle, 1 part by weight of Ephedra sinica, 2 parts by weight of Semi-Acer palmatum, 2 parts by weight of Gynostemma pentaphyllum, and 1 part by weight of Cinnamomum cassia. The preparation steps include: placing Dioscorea cirrhosa, Tinleaf Vine, Camphor Tree, Rhus chinensis, Rhododendron molle, Gynostemma pentaphyllum, Semi-Acer palmatum, Gynostemma pentaphyllum, and Cinnamomum cassia in 6000 parts by weight of 70% ethanol. Extract for 2 hours, repeat three times, filter, and combine the filtrates; concentrate, freeze-dry, pulverize, and pass through an 80-mesh sieve for later use; mix 27.5% freeze-dried powder with 26.45% citric acid, 34.11% sodium bicarbonate, 5.61% PEG6000, and 6.33% lactose evenly, pass through an 80-mesh sieve, and prepare a soft mass using anhydrous ethanol as a wetting agent; pass the soft mass through a 20-mesh sieve and dry at 37℃ for 30 minutes to obtain compound preparation granules; granulate through a 20-mesh sieve for granulation, add lubricant PEG6000 and mix evenly; compress into tablets to obtain compound preparation effervescent tablets. This invention, through pharmacological experiments, confirms that the Yaoyu effervescent tablet compound preparation has a good anti-rheumatoid arthritis effect: it can reduce local inflammatory mediators and serum IL-1β, IL-6, TNF-α, and PEG2 levels, downregulate MDA and increase SOD to improve oxidative stress, inhibit the expression of MMP3, COX-2, and P38 proteins in the synovial membrane, and reduce pathological tissue damage. The medium and high dose groups showed the best effect, and it has a good therapeutic and protective effect on the ankle joint of AA rats, with good clinical application value.

This invention belongs to the field of traditional Chinese medicine preparation technology, and provides a traditional Chinese medicine composition with anti-inflammatory, swelling-reducing, analgesic, and joint-relieving properties, its preparation method, and its application in the preparation of drugs for treating arthralgia. The method includes the following steps: Smilax glabra, Corydalis yanhusuo (processed with vinegar), and Stephania tetrandra are pulverized, mixed, decocted with water, filtered, the filtrate is concentrated, ethanol is added to precipitate, the supernatant is collected, the ethanol is recovered and concentrated to obtain a water-extracted alcohol-immersed extract, which is then mixed with maltodextrin, wet-granulated, and dried to obtain the traditional Chinese medicine composition. The traditional Chinese medicine composition obtained by this invention is based on the principles of promoting joint mobility, reducing swelling and relieving pain. It can significantly inhibit ankle joint swelling in rats with gouty arthritis, improve local inflammatory cell infiltration, and reduce synovial tissue hyperplasia in rats with gouty arthritis.

The present invention discloses a multi-component synovitis therapeutic composition based on cartilage tissue repair and a use thereof, relating to the technical field of biomedicine. The composition comprises glucosamine hydrochloride, chondroitin sulfate, dimethyl sulfone, and graded molecular weight sodium hyaluronate. By compounding these components in precise parts by weight, the present invention constructs a gradient sustained-release and targeted delivery system for synovitis lesions. Dimethyl sulfone specifically inhibits hyaluronidase activity in the inflamed joint cavity, significantly reducing sodium hyaluronate degradation and prolonging the retention time of each active ingredient at the lesion site. High molecular weight sodium hyaluronate rapidly forms a lubricating protective film to achieve immediate analgesia and relieve ankylosis, while medium- and low-molecular-weight sodium hyaluronate penetrates the synovial barrier and carries cartilage repair components to the cartilage defect area, thereby achieving synergistic enhancement and comprehensively improving synovitis treatment efficacy.

The application belongs to the technical field of medicine, and discloses application of a sesquiterpenoid compound in preparation of a drug for regulating synovial cells. The application first discloses a triple regulation mechanism of CJB on fibroblast-like synovial cells, i.e. inhibiting cell proliferation, reducing inflammatory reaction, and regulating ferroptosis pathway. Compared with a single-target drug, the multi-target effect mode can more comprehensively control the pathological process of RA, not only inhibits abnormal proliferation of FLS and secretion of inflammatory factors, but also removes pathological synovial cells by regulating ferroptosis and apoptosis, significantly improves the treatment effect, and reduces disease recurrence. Moreover, CJB has low toxicity, raw materials are easy to obtain, and can be used in combination with existing anti-rheumatic drugs, thereby reducing drug side effects and treatment costs.

A topical cream or ointment is provided that provides for the binding to CB1 and / or CB2 receptors for the soothing of pain, inflammation of smooth muscle, tendons, ligaments, skeletal muscle, endothelial cell, synovial cell, peripheral nerve fibers, reduction of endothelial bruising, promotion of healing of endothelial bruising, and dermatological itch sensation wherein the improvement comprises providing the effect of cannabinoid using plant extracts. A topically administered formulation is also provided for treating anal mucosal inflammation, soothing of pain, inflammation of anal mucosal inflammation; reducing keratinocyte apoptosis; treating viral-associated epithelial damage, treating radiation dermatitis; and treating chemotherapy-induced dermatitis.

This invention discloses a CH@SHP099-NPs composite hydrogel, its preparation method, and its applications, belonging to the field of biomedical technology. Addressing the technical challenge of achieving long-term, safe, and precise metabolic intervention with SHP2, this invention constructs a hydrogel system composed of chondroitin sulfate and hyaluronic acid. This system can retain SHP099-loaded nanoparticles within the joint cavity, forming a long-acting intrasynovial drug library, thereby continuously inhibiting the SHP2-AMPK signaling axis. The CH@SHP099-NPs composite hydrogel prepared in this invention can effectively reprogram the metabolic state of macrophages, reduce glycolysis flux, restore synovial immune metabolic homeostasis, and significantly improve synovial inflammation, chondrocyte activity, and cartilage structural integrity in vivo. This invention proposes a mechanism-guided local delivery metabolic intervention strategy, which is expected to provide a new interventional approach for the treatment of osteoarthritis.

This invention discloses an inflammatory pretreatment xenogeneic synovial cell-derived vesicle, its preparation method, and its application in the treatment of osteoarthritis, belonging to the field of biomedical technology. The preparation method includes: obtaining and culturing rabbit synovial fibroblast-like cells; subjecting the cells to inflammatory pretreatment for 40-60 hours using a culture medium containing 70-80 ng / mL tumor necrosis factor-α (TNF-α); collecting the cell supernatant, and purifying it by differential centrifugation and ultracentrifugation to obtain the vesicles. The vesicles have a particle size distribution of 100-1000 nm, with a higher proportion of larger particles (>800 nm) than natural vesicles. This invention also provides a pharmaceutical composition containing these vesicles and their application in the preparation of drugs for treating osteoarthritis. Experiments show that these vesicles can significantly inhibit subchondral ossification and osteophyte formation, effectively protect articular cartilage, and have a therapeutic effect superior to natural vesicles, providing a novel cell-free therapeutic strategy for osteoarthritis.

The present invention relates to a device for measuring, recording, and acting in response to changes in air pressures encountered through the lumen of a connected needle. The device signals when it has been powered and signals when the device recognizes both pressures and pressure change rates indicative of synovial cavity joint penetration, such as knee joint penetration. Synovial cavity pressures detected and acted upon may either be supra- (positive) or sub-atmospheric (negative). Internal light emitting diodes and a laptop connected display are demonstrated as signaling and communication mechanisms. Methods for delivering medicaments into human and animal intra-articular cavities or joints such as synovial cavities are provided. Furthermore, methods for facilitating the diagnoses of joint effusion also are provided.

The application provides a nucleic acid drug delivery carrier for efficiently targeting cartilage tissue, wherein a cationic lipid DOTAP is additionally added in a traditional four-component lipid nanoparticle to obtain a five-component lipid nanoparticle, and the five-component lipid nanoparticle is obtained by screening different ionizable lipids, phospholipid types, optimizing proportion relationships, particle sizes and electric potentials, and the five-component lipid nanoparticle has a hydration particle size less than 100 nm and a positive surface charge. In-vitro experiments show that the positive electric lipid nanoparticle has a transfection efficiency on chondrocytes obviously higher than that of a negative electric lipid nanoparticle, and can penetrate a whole layer of cartilage in a short time. Animal experiments show that the positive electric lipid nanoparticle has a significantly prolonged retention time in a joint cavity, a higher protein expression amount, and is mainly concentrated in cartilage tissue and almost not expressed in synovial membrane and other tissues. In a word, the application successfully realizes efficient targeting of cartilage tissue by using a simpler strategy, and has a simple method, uniform and stable quality, and can be produced in a large scale, and has an excellent conversion prospect.

This invention discloses a method, targets, and applications for the diagnosis and treatment of hemophilic arthritis. The method includes: obtaining cartilage and synovial membrane samples from patients with hemophilic arthritis undergoing total knee arthroplasty; performing single-cell RNA sequencing, single-cell ATAC sequencing, and spatial transcriptomics analysis to determine the main cell types and key cell subpopulations constituting the microenvironment of hemophilic arthritis; identifying the molecular characteristics and differentiation processes of chondrocyte and synovial fibroblast subpopulations; measuring intercellular interactions in the knee joint microenvironment of the samples; and identifying specific regulatory transcription factors in hemophilic arthritis through paired epigenetic analysis to identify diagnostic and therapeutic targets for hemophilic arthritis. This method integrates single-cell multi-omics analysis to analyze the cellular characteristics of synovial and cartilage tissues and their interactions in the epigenetic pathogenic mechanism, identifying potential therapeutic targets.

The application discloses application of a traditional Chinese medicine composition in preparation of a medicine for treating rheumatoid arthritis, and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition is prepared from the following raw medicinal materials in parts by weight: 20-60 parts of smilax glabra, 10-20 parts of achyranthes bidentata, 15-30 parts of radix paeoniae alba, 10-30 parts of giant knotweed, 6-20 parts of cortex fraxini, 3-10 parts of rhizoma coptidis, 6-20 parts of phellodendri chinensis, 10-30 parts of lily, and 6-20 parts of radix tinosporae. The traditional Chinese medicine composition can significantly improve the joint redness and swelling of a rheumatoid arthritis model animal, reduce an arthritis index, inhibit systemic and local joint inflammatory reactions, reduce synovial membrane proliferation, cartilage erosion and bone destruction, and is safe in use, thereby providing a safe and effective new scheme for clinical treatment of rheumatoid arthritis.